To prepare HIV-1 Vif and hAPOBEC3G and to produce their antibodies, the full length gene fragment of HIV-1 vif was amplified by PCR from a plasmid of HIV-1 NL4.3 cDNA, and the APOBEC3G gene was obtained by RT-PCR from the total RNA of H9 cells. The resulting DNA construct was cloned into a prokaryotic expression vector (pET-32a). Recombinant pET-vif and pET-APOBEC3G were expressed respectively in Eserichia coli BL21 (DE3) as an insoluble protein. The vector also contained a six-histidine tag at the C-terminus for convenient purification and detection. To express and purify the HIV-1 Vif and hAPOBEC3G in E.coli cells, the accuracy of inserted gene and specificity of proteins were detected by the two enzyme digestion method, SDS-PAGE, and Western blotting. Rabbits were then immunized by Vif or APOBEC3G protein and serum samples were tested by indirect ELISA to determine the level of antibodies. Immunoenzyme and immunofluorescence assays were performed to identify the specificity of polyclonal antibodies. The titer of the anti-Vif antibodies was 1:204800, and that of the anti-APOBEC3G antibodies was 1:102400. Thus the antibodies could detect the antigen expression in the cells, demonstrating that fusion proteins with high purity and their corresponding polyclonal antibodies with high titer and specificity were achieved.
Human immunodeficiency virus type 1 (HIV-1) Viral infectivity factor hAPOBEC3G Protein purification Polyclonal antibody
This is a preview of subscription content, log in to check access.
Doehle B P, Schafer A, Cullen B R. 2005. Human APOBEC3B is a potent inhibiror of HIV-1 infectivity and is rexistant to HIV-1Vif. Virology, 339(2): 281–288.PubMedCrossRefGoogle Scholar
Dussart S, Douaisi M, Courcoul M, et al. 2005. APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-l particles. J Mole Biol, 345(3): 547–558.CrossRefGoogle Scholar
Fisher A G, Ensoli B, Ivanoff L, et al. 1987. The sor gene of HIV-l is required for efficient virus transmissino in vitro. Science, 237: 888–893.PubMedCrossRefGoogle Scholar
Fujita M, Akari H, Sakurai A, et al. 2004. Expression of HIV-l accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect, 6: 791–798.PubMedCrossRefGoogle Scholar
Gabuzda D H, Lawrence K, Langhoff E, el al. 1992. Role of vif in replication of human immunodeficiency virus type l in CD4+T lymphocytes. J Virol, 66: 6489–6495.PubMedGoogle Scholar
Lee S K, Dykxhoorn D M, Kumar P, et al. 2005. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood, 106(3): 818–826.PubMedCrossRefGoogle Scholar
Luo K, Liu B, Xiao Z, et al. 2004. Amino-terminal region of the human immunodeficiency virus type l nucleocapsid is required for human APOBEC3G packaging. J Virol, 78(21): 11841–11852.PubMedCrossRefGoogle Scholar
Rose K M, Marin M, Kozak S L, et al. 2004. The Viral infectivity factou (Vif) of HIV-1 unveiled. Trends Mol Med, 10(6): 291–297.PubMedCrossRefGoogle Scholar
Sheehy A M, Gaddis N C, Choi J D, et al. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418: 646–650.PubMedCrossRefGoogle Scholar
Strebel K, Daugherty D, Clouse K, et al. 1987. The HIV ‘A’ (sor) gene product is essential for vius infectivity. Nature, 328: 728–730.PubMedCrossRefGoogle Scholar
Von S U, Song J, Aiken C, et al. 1993. Vif is crucial for human immunodeficiency virus type I proviral DNA synthesis in infected cells. J Virol, 67: 4945–4955.Google Scholar
Wang H, Sakurai A, Khamsri B, et al. 2005. Unique characteristics of HIV-1 Vif expression. Microbes Infect, 7(3): 385–390.PubMedCrossRefGoogle Scholar